The abstract is read at the publisher; the summary is JClub's.
Urine cotinine concentrations among adolescents receiving substance use disorder treatment who vape nicotine are tracked for trends from 2023 to 2025.
- Why it matters: Cotinine is a biomarker of nicotine exposure, and monitoring its trend helps quantify changes in vaping-related exposure during treatment.
- What they did: In a cohort design, urine cotinine concentrations were measured across 2023–2025 in adolescents who vaped nicotine and were receiving substance use disorder treatment.
- The result: The study characterizes how urine cotinine levels change over time in this treated adolescent vaping group, informing interpretation of nicotine exposure trends.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.